Re: A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: The cancer and osteoporosis research with alendronate and leuprolide (CORAL) study: Editorial comment

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Original languageEnglish (US)
    Number of pages1
    JournalJournal of Urology
    Volume189
    Issue number5
    DOIs
    StatePublished - May 2013

    ASJC Scopus subject areas

    • Urology

    Cite this